| Gene Symbol | HLA-E |
| Entrez ID | 3133 |
| Uniprot ID | P13747 |
| Description | major histocompatibility complex, class I, E |
| Chromosomal Location | chr6: 30,489,467-30,494,205 |
| Ontology | GO ID | GO Term | Definition | Evidence |
|---|---|---|---|---|
|
BP |
GO:0001916 |
positive regulation of T cell mediated cytotoxicity |
Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity. |
IDA |
|
BP |
GO:0002250 |
adaptive immune response |
An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory). |
IDA |
|
BP |
GO:0002474 |
antigen processing and presentation of peptide antigen via MHC class I |
The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules. |
IBA|TAS |
|
BP |
GO:0002476 |
antigen processing and presentation of endogenous peptide antigen via MHC class Ib |
The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class Ib protein complex. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family. |
IDA |
|
BP |
GO:0002479 |
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent |
The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules. |
TAS |
|
BP |
GO:0002480 |
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent |
The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules. |
TAS |
|
BP |
GO:0002715 |
regulation of natural killer cell mediated immunity |
Any process that modulates the frequency, rate, or extent of natural killer cell mediated immunity. |
IDA |
|
BP |
GO:0002717 |
positive regulation of natural killer cell mediated immunity |
Any process that activates or increases the frequency, rate, or extent of natural killer cell mediated immunity. |
IDA |
|
BP |
GO:0019731 |
antibacterial humoral response |
An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster. |
IDA |
|
BP |
GO:0032736 |
positive regulation of interleukin-13 production |
Any process that activates or increases the frequency, rate, or extent of interleukin-13 production. |
IDA |
|
BP |
GO:0032753 |
positive regulation of interleukin-4 production |
Any process that activates or increases the frequency, rate, or extent of interleukin-4 production. |
IDA |
|
BP |
GO:0032759 |
positive regulation of TRAIL production |
Any process that activates or increases the frequency, rate, or extent of TRAIL production. |
IDA |
|
BP |
GO:0032760 |
positive regulation of tumor necrosis factor production |
Any process that activates or increases the frequency, rate, or extent of tumor necrosis factor production. |
IDA |
|
BP |
GO:0036037 |
CD8-positive, alpha-beta T cell activation |
The change in morphology and behavior of a CD8-positive, alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific. |
IDA |
|
BP |
GO:0042270 |
protection from natural killer cell mediated cytotoxicity |
The process of protecting a cell from natural killer cell mediated cytotoxicity. |
IDA |
|
BP |
GO:0045087 |
innate immune response |
Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
TAS |
|
BP |
GO:0050776 |
regulation of immune response |
Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus. |
TAS |
|
BP |
GO:0050830 |
defense response to Gram-positive bacterium |
Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism. |
IDA |
|
BP |
GO:0051024 |
positive regulation of immunoglobulin secretion |
Any process that activates or increases the frequency, rate or extent of the regulated release of immunoglobulins from a cell. |
IDA |
|
BP |
GO:0060333 |
interferon-gamma-mediated signaling pathway |
A series of molecular signals initiated by the binding of interferon-gamma to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far. |
TAS |
|
BP |
GO:0060337 |
type I interferon signaling pathway |
A series of molecular signals initiated by the binding of a type I interferon to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. |
TAS |
|
BP |
GO:2000566 |
positive regulation of CD8-positive, alpha-beta T cell proliferation |
Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation. |
IDA |
|
CC |
GO:0000139 |
Golgi membrane |
The lipid bilayer surrounding any of the compartments of the Golgi apparatus. |
TAS |
|
CC |
GO:0005886 |
plasma membrane |
The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
TAS |
|
CC |
GO:0009986 |
cell surface |
The external part of the cell wall and/or plasma membrane. |
IDA |
|
CC |
GO:0012507 |
ER to Golgi transport vesicle membrane |
The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi. |
TAS |
|
CC |
GO:0030670 |
phagocytic vesicle membrane |
The lipid bilayer surrounding a phagocytic vesicle. |
TAS |
|
CC |
GO:0031901 |
early endosome membrane |
The lipid bilayer surrounding an early endosome. |
TAS |
|
CC |
GO:0032398 |
MHC class Ib protein complex |
A transmembrane protein complex composed of a MHC class Ib alpha chain and, in most cases, an invariant beta2-microglobin chain, and with or without a bound peptide or lipid antigen. Class Ib here refers to non-classical class I molecules, such as those of the CD1 or HLA-E gene families. |
IDA |
|
CC |
GO:0042612 |
MHC class I protein complex |
A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules. |
IDA |
|
CC |
GO:0070062 |
extracellular exosome |
A membrane-bounded vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
IDA |
|
CC |
GO:0071556 |
integral component of lumenal side of endoplasmic reticulum membrane |
The component of the endoplasmic reticulum membrane consisting of the gene products that penetrate only the lumenal side of the membrane. |
TAS |
|
MF |
GO:0005102 |
receptor binding |
Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
IPI |
|
MF |
GO:0030881 |
beta-2-microglobulin binding |
Interacting selectively and non-covalently with beta-2-microglobulin. |
IDA|IMP |
|
MF |
GO:0042288 |
MHC class I protein binding |
Interacting selectively and non-covalently with major histocompatibility complex class I molecules; a set of molecules displayed on cell surfaces that are responsible for lymphocyte recognition and antigen presentation. |
IDA |
|
MF |
GO:0042605 |
peptide antigen binding |
Interacting selectively and non-covalently with an antigen peptide. |
IDA|IMP |
|
MF |
GO:0046703 |
natural killer cell lectin-like receptor binding |
Interacting selectively and non-covalently with a lectin-like natural killer cell receptor. |
IPI |
| Domain ID | Description |
|---|---|
|
IPR001039 |
MHC class I alpha chain, alpha1 alpha2 domains |
|
IPR003006 |
Immunoglobulin/major histocompatibility complex, conserved site |
|
IPR003597 |
Immunoglobulin C1-set |
|
IPR007110 |
Immunoglobulin-like domain |
|
IPR010579 |
MHC class I, alpha chain, C-terminal |
|
IPR011161 |
MHC class I-like antigen recognition-like |
|
IPR011162 |
MHC classes I/II-like antigen recognition protein |
|
IPR013783 |
Immunoglobulin-like fold |
| Pathway ID | Pathway Term | Pathway Source |
|---|---|---|
|
hsa04144 |
Endocytosis |
KEGG |
|
hsa04145 |
Phagosome |
KEGG |
|
hsa04514 |
Cell adhesion molecules (CAMs) |
KEGG |
|
hsa04612 |
Antigen processing and presentation |
KEGG |
|
hsa04650 |
Natural killer cell mediated cytotoxicity |
KEGG |
|
hsa04940 |
Type I diabetes mellitus |
KEGG |
|
hsa05166 |
HTLV-I infection |
KEGG |
|
hsa05168 |
Herpes simplex infection |
KEGG |
|
hsa05169 |
Epstein-Barr virus infection |
KEGG |
|
hsa05203 |
Viral carcinogenesis |
KEGG |
|
hsa05320 |
Autoimmune thyroid disease |
KEGG |
|
hsa05330 |
Allograft rejection |
KEGG |
|
hsa05332 |
Graft-versus-host disease |
KEGG |
|
hsa05416 |
Viral myocarditis |
KEGG |
|
WP2328 |
Allograft Rejection |
WikiPathways |
|
WP183 |
Proteasome Degradation |
WikiPathways |
| UMLS CUI | UMLS Term |
|---|---|
|
C0030491 |
Parapsoriasis |
| Tissue | Cell Type |
|---|---|
|
kidney |
cells in glomeruli |
|
lymph node |
non-germinal center cells |
|
tonsil |
non-germinal center cells |
| Pubmed ID | Author | Year | Title |
|---|---|---|---|
|
22617121 |
Ouandaogo et al. |
2012 |
Differences in transcriptomic profiles of human cumulus cells isolated from oocytes at GV, MI and MII stages after in vivo andin vitro oocyte maturation |
|
22951915 |
Haozi et al. |
2012 |
Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome |
| Gene Symbol | Entrez ID | Uniprot ID | Score |
|---|---|---|---|
|
HLA-E |
3133 |
P13747 |
0.62 |
|
ABCA3 |
21 |
Q99758 |
0.63 |
|
ASPH |
444 |
Q12797 |
0.63 |
|
COX5B |
1329 |
P10606 |
0.63 |
|
ATF6B |
1388 |
Q99941 |
0.63 |
|
EPHB4 |
2050 |
P54760 |
0.63 |
|
FCGRT |
2217 |
P55899 |
0.63 |
|
GAS6 |
2621 |
Q14393 |
0.63 |
|
HLA-A |
3105 |
P30443 |
0.63 |
|
HLA-DPB1 |
3115 |
P04440 |
0.63 |
|
HLA-F |
3134 |
P30511 |
0.63 |
|
HLA-H |
3136 |
P01893 |
0.63 |
|
MR1 |
3140 |
Q95460 |
0.63 |
|
NDST1 |
3340 |
P52848 |
0.63 |
|
ITGA6 |
3655 |
P23229 |
0.63 |
|
KCNJ8 |
3764 |
Q15842 |
0.63 |
|
MAN2A2 |
4122 |
P49641 |
0.63 |
|
MGAT5 |
4249 |
Q09328 |
0.63 |
|
RPL31 |
6160 |
P62899 |
0.63 |
|
TRAPPC2 |
6399 |
P0DI81 |
0.63 |
|
NEK4 |
6787 |
P51957 |
0.63 |
|
NDST2 |
8509 |
P52849 |
0.63 |
|
MADD |
8567 |
Q8WXG6 |
0.63 |
|
FAM127A |
8933 |
O15255 |
0.63 |
|
ECEL1 |
9427 |
O95672 |
0.63 |
|
EIF2AK3 |
9451 |
Q9NZJ5 |
0.63 |
|
ARFGEF2 |
10564 |
Q9Y6D5 |
0.63 |
|
FAM189B |
10712 |
P81408 |
0.63 |
|
ATF6 |
22926 |
P18850 |
0.63 |
|
WDFY3 |
23001 |
Q8IZQ1 |
0.63 |
|
TMEM131 |
23505 |
Q92545 |
0.63 |
|
PLXNB2 |
23654 |
O15031 |
0.63 |
|
BACE2 |
25825 |
Q9Y5Z0 |
0.63 |
|
CNNM1 |
26507 |
Q9NRU3 |
0.63 |
|
METTL13 |
51603 |
Q8N6R0 |
0.63 |
|
PLXNA3 |
55558 |
P51805 |
0.63 |
|
EDEM2 |
55741 |
Q9BV94 |
0.63 |
|
PBXIP1 |
57326 |
Q96AQ6 |
0.63 |
|
GALNT12 |
79695 |
Q8IXK2 |
0.63 |
|
PTCD2 |
79810 |
Q8WV60 |
0.63 |
|
TCTN2 |
79867 |
Q96GX1 |
0.63 |
|
CNTNAP3 |
79937 |
Q9BZ76 |
0.63 |
|
PPP1R16A |
84988 |
Q96I34 |
0.63 |
|
ATP23 |
91419 |
Q9Y6H3 |
0.63 |
|
TAP2 |
6891 |
Q03519 |
0.72 |
|
CALR |
811 |
P27797 |
0.82 |
|
B2M |
567 |
P61769 |
0.89 |
|
CD8A |
925 |
P01732 |
0.52 |
|
KLRC1 |
3821 |
P26715 |
0.52 |
|
KLRC2 |
3822 |
P26717 |
0.62 |
|
AKT2 |
208 |
P31751 |
0.63 |
|
HLA-B |
3106 |
P01889 |
0.63 |
|
HLA-C |
3107 |
P30499 |
0.63 |
|
HERC2 |
8924 |
O95714 |
0.63 |
|
UBD |
10537 |
O15205 |
0.63 |
|
KLRD1 |
3824 |
Q13241 |
0.86 |